Advancements in Myeloma Treatment and the Shift towards MRD Negativity

This chapter discusses the progress made in myeloma treatment over the years and the paradigm shift towards achieving MRD negativity. It explores various phase three trials, such as the Perseus study and the Iskia trial, comparing different treatment regimens and focusing on high-risk patients. The chapter also highlights the importance of depth of response in clinical trials and the potential of bi-specific antibodies in myeloma treatment.